Repligen (NASDAQ:RGEN) Given Buy Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of Repligen (NASDAQ:RGEN) in a research note released on Friday morning,Benzinga reports. HC Wainwright currently has a $180.00 price target on the biotechnology company’s stock.

Other analysts have also recently issued research reports about the stock. Canaccord Genuity Group began coverage on shares of Repligen in a research note on Tuesday, December 17th. They set a “hold” rating and a $165.00 target price on the stock. StockNews.com upgraded Repligen from a “sell” rating to a “hold” rating in a research report on Friday, January 3rd. TD Cowen began coverage on Repligen in a research report on Monday, February 10th. They issued a “buy” rating and a $200.00 target price for the company. Wolfe Research assumed coverage on Repligen in a report on Thursday, November 14th. They set a “peer perform” rating on the stock. Finally, Canaccord Genuity Group began coverage on shares of Repligen in a report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price objective for the company. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $181.00.

Repligen Stock Performance

NASDAQ:RGEN opened at $158.99 on Friday. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. The firm has a market capitalization of $8.91 billion, a PE ratio of -311.75, a price-to-earnings-growth ratio of 4.54 and a beta of 0.99. Repligen has a twelve month low of $113.50 and a twelve month high of $203.13. The stock’s 50-day simple moving average is $155.22 and its 200 day simple moving average is $148.59.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.41 by $0.03. The company had revenue of $167.55 million for the quarter, compared to analyst estimates of $167.58 million. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. On average, analysts anticipate that Repligen will post 1.72 EPS for the current fiscal year.

Institutional Trading of Repligen

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. GTS Securities LLC bought a new position in shares of Repligen during the fourth quarter valued at about $264,000. Gordian Capital Singapore Pte Ltd purchased a new stake in Repligen in the 4th quarter valued at about $259,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in Repligen by 12.8% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 235,343 shares of the biotechnology company’s stock valued at $33,875,000 after buying an additional 26,733 shares during the last quarter. Two Sigma Advisers LP lifted its position in shares of Repligen by 6.7% during the 4th quarter. Two Sigma Advisers LP now owns 134,800 shares of the biotechnology company’s stock worth $19,403,000 after buying an additional 8,500 shares in the last quarter. Finally, Raiffeisen Bank International AG bought a new position in shares of Repligen in the fourth quarter valued at approximately $29,000. 97.64% of the stock is owned by institutional investors.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.